MYGN Financial Facts

Research and development expense: 16.7M
Companion diagnostic services: 10.7M
See Full Income Statement

Marketable investment securities: 84.6M
Accrued liabilities: 47.9M
See Full Balance Sheet

Myriad Genetics Inc. (MYGN) Earnings

  |   Expand Research on MYGN
Next EPS Date 5/4/16 *Est. EPS Growth Rate +12.5% *Last Qtr.
Average EPS % Beat Rate +6.8% Revenue Growth Rate +4.8% *Last Qtr.
Average % Move 1-Wk after EPS +1.9% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
2/2/16 Q216 $0.45$0.41 +$0.04$193.3M$189.97M Details
11/3/15 Q116 $0.41$0.35 +$0.06$183.5M$177.89M Details
8/11/15 Q415 $0.41$0.42 -$0.01$189.9M$187.77M Details
5/5/15 Q315 $0.40$0.39 +$0.01$180M$183.3M = Details
2/3/15 Q215 $0.40$0.35 +$0.05$184.4M$183.41M = Details
11/4/14 Q115 $0.25$0.32 -$0.07$168.8M$175M = Details
8/12/14 Q414 $0.48$0.46 +$0.02$188.8M$187.68M = Details
5/6/14 Q314 $0.48$0.45 +$0.03$176.2M$175.23M = Details